Dynasty Wealth Management LLC Has $1.17 Million Holdings in Kenvue Inc. (NYSE:KVUE)

Dynasty Wealth Management LLC boosted its position in shares of Kenvue Inc. (NYSE:KVUE) by 30.5% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 54,589 shares of the company’s stock after acquiring an additional 12,759 shares during the period. Dynasty Wealth Management LLC’s holdings in Kenvue were worth $1,165,000 at the end of the most recent quarter.

A number of other hedge funds also recently bought and sold shares of KVUE. CORDA Investment Management LLC. lifted its holdings in shares of Kenvue by 1.4% during the fourth quarter. CORDA Investment Management LLC. now owns 1,253,096 shares of the company’s stock worth $26,754,000 after buying an additional 17,466 shares during the last quarter. QRG Capital Management Inc. bought a new position in Kenvue during the fourth quarter worth $218,000. Versor Investments LP acquired a new position in Kenvue during the 4th quarter valued at $333,000. Proficio Capital Partners LLC bought a new stake in Kenvue in the 4th quarter valued at $1,643,000. Finally, Kovack Advisors Inc. acquired a new stake in Kenvue in the 4th quarter worth $267,000. 97.64% of the stock is currently owned by institutional investors.

Kenvue Price Performance

Shares of Kenvue stock opened at $23.58 on Friday. Kenvue Inc. has a 1-year low of $17.67 and a 1-year high of $24.46. The firm’s 50-day moving average price is $21.46 and its two-hundred day moving average price is $22.26. The company has a current ratio of 1.00, a quick ratio of 0.69 and a debt-to-equity ratio of 0.66. The stock has a market capitalization of $45.07 billion, a price-to-earnings ratio of 44.49, a P/E/G ratio of 2.62 and a beta of 1.45.

Kenvue (NYSE:KVUE) last released its quarterly earnings results on Thursday, February 6th. The company reported $0.26 EPS for the quarter, hitting analysts’ consensus estimates of $0.26. Kenvue had a return on equity of 20.97% and a net margin of 6.66%. On average, equities analysts predict that Kenvue Inc. will post 1.14 earnings per share for the current fiscal year.

Kenvue Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Wednesday, February 26th. Investors of record on Wednesday, February 12th were issued a $0.205 dividend. The ex-dividend date of this dividend was Wednesday, February 12th. This represents a $0.82 dividend on an annualized basis and a dividend yield of 3.48%. Kenvue’s dividend payout ratio is 154.72%.

Wall Street Analyst Weigh In

KVUE has been the topic of several research reports. Barclays dropped their price objective on shares of Kenvue from $23.00 to $21.00 and set an “equal weight” rating on the stock in a report on Friday, January 17th. Citigroup lowered their price target on Kenvue from $25.00 to $21.00 and set a “neutral” rating on the stock in a research note on Wednesday, January 15th. UBS Group reduced their price objective on Kenvue from $23.00 to $21.00 and set a “neutral” rating for the company in a research report on Friday, February 7th. Deutsche Bank Aktiengesellschaft cut Kenvue from a “buy” rating to a “hold” rating and lowered their price objective for the company from $25.00 to $24.00 in a research report on Thursday, December 12th. Finally, Piper Sandler upped their target price on Kenvue from $24.00 to $27.00 and gave the company an “overweight” rating in a research note on Monday, February 24th. One equities research analyst has rated the stock with a sell rating, eight have assigned a hold rating and five have given a buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $23.08.

Kenvue Company Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.